6533b826fe1ef96bd128461c
RESEARCH PRODUCT
ANGIOMET: Analysis of the correlations between angiogenic markers and outcome in patients (p) with advanced nonsquamous NSCLC (NS-NSCLC) treated with carboplatin, paclitaxel, and bevacizumab (CPB).
Mariano ProvencioAngel ArtalMaria Sanchez RoncoEloisa Jantus-lewintreJavier De CastroJose Luis Gonzalez ArribaI. MaestuRafael RosellRamon De Las PenasJ. GardeJuana OramasBartomeu MassutiOscar JuanRamón García GómezCarlos CampsChristian RolfoDelvys Rodriguez AbreuManuel DomineRamon Maria Perez CarrionJ. Terrasasubject
OncologyCancer Researchmedicine.medical_specialtyBevacizumabbusiness.industryCarboplatin/paclitaxelOncologyVegf pathwayInternal medicinemedicineIn patientbusinessReceptormedicine.drugdescription
e19014 Background: In NS-NSCLC CPB achieved median OS > 1 y and supported use of B. A broad range of predictive/prognostic markers explored for B use. In VEGF pathway ligands and receptors play an ...
year | journal | country | edition | language |
---|---|---|---|---|
2014-05-20 | Journal of Clinical Oncology |